Outcomes | Unmatched | Â | After PSM | Â | After IPTW | |||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
Sugammadex (n = 92) | Neostigmine (n = 113) | OR/MDa (95% CI) | P value |  | Sugammadex (n = 38) | Neostigmine (n = 38) | OR/MDa (95% CI) | P value |  | OR/MDa (95% CI) | P value | |
PONV | 13 (14.1) | 76 (67.3) | 0.08 (0.04–0.16) | < 0.001b |  | 5 (13.2) | 26 (68.4) | 0.07 (0.02–0.22) | < 0.001b |  | 0.54 (0.48–0.61) | < 0.001b |
PON | 5 (5.4) | 15 (13.3) | 0.38 (0.13–1.08) | 0.060 |  | 4 (10.5) | 7 (18.4) | 0.52 (0.14–1.90) | 0.328 |  | 0.77 (0.67–0.88) | < 0.001b |
POV | 8 (8.7) | 61 (54.0) | 0.08 (0.04–0.18) | < 0.001b |  | 1 (2.6) | 19 (50.0) | 0.03 (0.01–0.22) | < 0.001b |  | 0.60 (0.53–0.68) | < 0.001b |
Rescue antiemetic therapy | 4 (4.3) | 38 (33.6) | 0.09 (0.03–0.26) | < 0.001b |  | 1 (2.6) | 16 (42.1) | 0.04 (0.01–0.30) | < 0.001b |  | 0.70 (0.62–0.80) | < 0.001b |
Water intake | 1882.4 ± 485.5 | 1436.5 ± 526.4 | 445.8 (305.1–586.6) | < 0.001b |  | 1932.9 ± 407.2 | 1510.5 ± 474.2 | 422.4 (220.3–624.4) | 0.001b |  | 419.5 (214.2–613.6) | < 0.001b |